EUVIMEDEUVIMED entdecken
Crossref

2453-P: Long-Term Intranasal Insulin Enhances Hypothalamic Insulin Sensitivity and Reduces Adiposity in Adults with Overweight or Obesity

LEONTINE SANDFORTH, RALF VEIT, CORINNA DANNECKER, REINER J. VON SCHWARTZENBERG, ANDREAS VOSSELER, MANFRED HALLSCHMID, ROBERT WAGNER, ANDREAS L. BIRKENFELD, PREISSL HUBERT, ANDREAS FRITSCHE, MARTIN HENI, STEPHANIE KULLMANN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2453-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von LEONTINE SANDFORTH und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Brain insulin sensitivity plays a central role in coordinating whole-body metabolism. In humans, reduced brain insulin responsiveness is linked to weight gain, visceral adiposity, and impaired metabolic control. Experimental work shows that intranasal insulin (INI) delivers insulin to the brain with minimal systemic effects. Building on this concept, we aimed to enhance central insulin signaling in humans through long-term INI treatment. We hypothesized that INI treatment enhances brain insulin sensitivity while leading to a more favorable body fat distribution.

Methods

In this randomized, controlled, blinded study, 39 healthy individuals (age 60.6 ± 7.4 years; 67% women) were randomized to daily INI (160 IU, n=19) or placebo (PLA, n=20) spray treatment for 8 weeks. Before (t=0) and after (t=8wk) the treatment period, individuals were deeply phenotyped, including whole-body MRI for body fat quantification and functional MRI combined with acute INI to assess brain insulin sensitivity. Data are displayed as median ± 95% CI.

Results

Body mass index (BMI) was similar between groups at baseline (t=0, INI: 28.2 ± 2.3 vs PLA 29.7 ± 3.1 kg/m2; p=0.51) and decreased only in the INI group (t=8wk, BMI: INI 27.3 ± 2.3, vs t=0; p=0.046, PLA: 30.2 ± 3.0 kg/m2, vs t=0; p=0.14). This was paralleled by a reduction in subcutaneous adipose tissue in the INI but not in the PLA group (Time point X Treatment p=0.01; t=0 vs t=8wk: INI 13.3 ± 2.2 L vs 12.5 ± 2.3 L; p=0.03; PLA 14.0 ± 2.7 L vs 15.4 ± 3.0 L; p=0.93). Hypothalamic insulin sensitivity increased in the INI but not in the placebo group (Time point X Treatment p=0.01; t=0 vs t=8wk: INI p=0.007; PLA p>0.99).

Conclusion

Chronic INI treatment improves hypothalamic insulin sensitivity in adults with overweight or obesity, and this effect is accompanied by a reduction in BMI and subcutaneous fat. These findings highlight brain insulin responsiveness as a therapeutic target to counteract elevated body weight and body fat content. Disclosure L. Sandforth: None. R. Veit: None. C. Dannecker: None. R.J. von Schwartzenberg: None. A. Vosseler: None. M. Hallschmid: None. R. Wagner: Advisory Panel; Current; Sanofi. Speaker's Bureau; Ended; Daiichi Sankyo, Novo Nordisk. A.L. Birkenfeld: None. P. Hubert: None. A. Fritsche: None. M. Heni: Advisory Panel; Ended; Chiesi USA, Inc. Speaker's Bureau; Ended; Chiesi USA, Inc. Advisory Panel; Ended; Boehringer Ingelheim International GmbH. Speaker's Bureau; Ended; Boehringer Ingelheim International GmbH, AstraZeneca, Lilly, Novartis AG, Novo Nordisk, Bayer AG. S. Kullmann: None.

Zitieren

APA

SANDFORTH, L., VEIT, R., DANNECKER, C., SCHWARTZENBERG, R. J. V., VOSSELER, A., HALLSCHMID, M., WAGNER, R., BIRKENFELD, A. L., HUBERT, P., FRITSCHE, A., HENI, M., & KULLMANN, S. (2026). 2453-P: Long-Term Intranasal Insulin Enhances Hypothalamic Insulin Sensitivity and Reduces Adiposity in Adults with Overweight or Obesity. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2453-p

Vancouver

SANDFORTH L, VEIT R, DANNECKER C, SCHWARTZENBERG RJV, VOSSELER A, HALLSCHMID M, et al. 2453-P: Long-Term Intranasal Insulin Enhances Hypothalamic Insulin Sensitivity and Reduces Adiposity in Adults with Overweight or Obesity. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2453-p

BibTeX
@article{SANDFORTH2026,
  author = {SANDFORTH, LEONTINE and VEIT, RALF and DANNECKER, CORINNA and SCHWARTZENBERG, REINER J. VON and VOSSELER, ANDREAS and HALLSCHMID, MANFRED and WAGNER, ROBERT and BIRKENFELD, ANDREAS L. and HUBERT, PREISSL and FRITSCHE, ANDREAS and HENI, MARTIN and KULLMANN, STEPHANIE},
  title = {2453-P: Long-Term Intranasal Insulin Enhances Hypothalamic Insulin Sensitivity and Reduces Adiposity in Adults with Overweight or Obesity},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2453-p}
}
Kostenlos starten →